TG Therapeutics, Inc.

NASDAQ:TGTX

Biotechnology

Healthcare
$66.12 +2.00%

+$1.03 today

Market cap
$9.99B
Beta
1.68
P/E (TTM)
16.4
EPS (TTM)
$3.20
52W Low $25.28High $53.98

Volume 1.87M

Average 2.15M

TGTX EBITDA Margin

EBITDA as a percentage of revenue.

TG Therapeutics, Inc.NASDAQ: TGTX

EBITDA Margin · Q3 FY2026 · quarter ended Sep 2026

EBITDA Margin widens to 34.5%

EBITDA Margin was 34.5% in Q3 FY2026, up 14.3 pp from a year earlier. On a trailing-twelve-month basis it was 21.3%, down 0.4 pp year over year. Over 3 fiscal years it widened by 7673.7 pp.

Context

  • EBITDA Margin widened in 3 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 5 analysts of 21.8% for the fiscal year ending Dec 2026, down from 21.8% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
34.5%+25.5 pp QoQ
Last fiscal yearDec 2025
21.8%+6.6 pp YoY
LTMSep 2026
21.3%-0.4 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+14.3 pp-57.2 pp-71.5 pp
1 year+6.6 pp-0.1 pp-6.7 pp
3 years+7673.7 pp+22.1 pp-7651.7 pp
5 years+27.3 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
21.8%
Year-over-year change
+6.6pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How TGTX compares with its peers on the latest reported figures

  • TGTX's LTM Sep 2026 EBITDA Margin of 21.3% is the 2nd highest of the 8 companies compared; the peer median is -117.7%.
  • Its year-over-year change of -0.4 pp is the 2nd highest of 6, against a peer median of -51.9 pp.
  • Over three fiscal years its change of +7673.7 pp compares with a peer median of -14.7 pp.
TGTX Competitors Peer median
EBITDA Margin for TGTX and competitors
Company Period LTM level YoY 3-year change
GMABGenmab A/SLTM Jun 202629.5% —-14.7 pp
TGTXTG Therapeutics, Inc.LTM Sep 202621.3% -0.4 pp+7673.7 pp
MGNXMacroGenics, Inc.LTM Mar 2026-32.2% -1.2 pp+32.0 pp
ADCTADC Therapeutics S.A.LTM Mar 2026-105.1% +22.1 pp-58.4 pp
XNCRXencor, Inc.LTM Jun 2026-117.7% -51.9 pp-9.6 pp
IPHAInnate Pharma S.A.FY2025-1566.1% -1194.4 pp-1544.8 pp
ADAGAdagene Inc.LTM Jun 2024-4420.7% —+613.1 pp
CLDXCelldex Therapeutics, Inc.LTM Sep 2026-272652.7% -264146.9 pp-12607.1 pp
CRVSCorvus Pharmaceuticals, Inc.FY2025— ——
Peer median (excluding TGTX) -117.7%-51.9 pp-14.7 pp

Competitors are the stored peer set for TGTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue6.69M2.79M233.66M329M616.29M
Cost of Revenue790K265K14.13M38.49M100.71M
Gross Profit5.9M2.52M219.53M290.52M515.57M
Gross Margin88.2%90.5%94.0%88.3%83.7%
Research & Development222.58M125.35M76.19M94.29M160.22M
Selling, General & Admin128.09M95.48M122.71M154.3M232.03M
Operating Expenses350.67M220.84M198.9M248.59M392.25M
Depreciation & Amortization494K515K423K280K244K
EBITDA(341.97M)(213.11M)26.1M49.9M134.36M
EBITDA Margin-5112.4%-7651.9%11.2%15.2%21.8%
Operating Income(344.77M)(218.32M)20.63M41.93M123.32M
Operating Margin-5154.3%-7839.0%8.8%12.7%20.0%
Interest Income00000
Interest Expense5.64M10.19M12.62M24.03M26.73M
Other Income / Expenses(3.33M)(5.5M)(7.57M)(16.34M)(15.93M)
Income Before Tax(348.1M)(223.81M)13.06M25.59M107.39M
Pre-Tax Margin-5204.1%-8036.3%5.6%7.8%17.4%
Income Tax Expense00390K2.21M(339.79M)
Net Income(348.1M)(223.81M)12.67M23.38M447.18M
Net Margin-5204.1%-8036.3%5.4%7.1%72.6%
EPS (Basic)(2.63)(1.46)0.090.163.10
EPS (Diluted)(2.63)(1.46)0.090.152.77
Weighted Avg Shares132.22M135.41M141.96M145.32M144.32M
Weighted Avg Shares (Diluted)132.22M135.41M148.51M160.34M161.41M

TG Therapeutics, Inc.

NASDAQ:TGTX

Intrinsic Alpha fair value

Locked

Current Price

$66.12

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.